Evaluating the Pharmacokinetics, Feasibility, Acceptability, and Safety of Oral Pre-Exposure Prophylaxis for HIV Prevention During Pregnancy and Postpartum

NCT03386578 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

780

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)
BEHAVIORAL: Behavioral HIV risk reduction package
BEHAVIORAL: Enhanced adherence support

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborators

[object Object]